

Contacts Media

Amsterdam +31 20 721 4133
Dublin +353 1 617 4249
Milan +39 02 72 42 62 12
Paris +33 1 70 48 24 45

Brussels +32 2 620 15 50
Lisbon +351 210 600 614
Oslo +47 22 34 19 15

Contact Investor Relations

+33 1 70 48 24 27

Ulisse Biomed S.p.A. lists on AIM Italia

- **Twenty-second listing of 2021 on Borsa Italiana's AIM Italia**
- **Ulisse Biomed S.p.A. brings the total number of companies listed on Borsa Italiana's AIM Italia to 153**
- **Total placement volume of the offering equal to €5 million with listing**



Milan – 6 August 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Ulisse Biomed S.p.A. on its listing on Borsa Italiana's AIM Italia.

Ulisse Biomed S.p.A. is a healthcare biotech company operating in the diagnostics, theranostics and therapeutics.

Ulisse Biomed S.p.A. is the twenty-second company to list since the beginning of the year on Borsa Italiana's market dedicated to small and medium-sized companies and brings the total number of firms currently listed on AIM Italia to 153.

In the placement phase, Ulisse Biomed S.p.A. raised €4.5 million, excluding the potential exercise of an over-allotment option. In case of the full exercise of the over-allotment option, the total amount raised will be €5 million. The free float at the time of admission was 31,82% and the market capitalisation at IPO was €14.5 million.

Matteo Petti, CEO, Ulisse Biomed S.p.A., said: *"The listing today will allow us to finance our growth and bring to the market the products that are on our technological platforms, enhancing, in this way, our visibility, standing and confirming our independent growth. We will continue to focus our efforts in order to make personalised treatments an affordable reality to everyone, using the countless opportunities offered by the use of DNA, for the benefit of our company and our shareholders. We present ourselves to the market with the structure of a public company, hoping to meet expectations with positive results and the trust that has been placed in us."*



Matteo Petti, CEO of Ulisse Biomed S.p.A. rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.

CONTACTS MEDIA – mediateam@euronext.com

Andrea Monzani (Milan/Rome)
Federica Marotti (Milan/Rome)
Ester Russom (Milan/Rome)

+39 02 72 42 62 12

media.relations@borsaitaliana.it

Ulisse Biomed S.p.A.

Ulisse Biomed S.p.A. is a healthcare biotech company operating in the diagnostics, theranostics and therapeutics with the mission to develop innovative solutions in these fields. The company has three proprietary technology platforms capable of generating innovative and competitive products: Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). UBM owns a portfolio of intellectual properties made of 8 international patent applications that cover the three technology platforms (3 related to Sagitta, 2 related to NanoHybrid, 1 related to Aptavir and 2 transversal to the three platforms), two of them are granted in Italy and in Europe.

About Euronext

Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,900 listed issuers and around €6.4 trillion in market capitalisation as of end June 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal.

For the latest news, go to euronext.com or follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2021, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the



processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.

